Omega-3 Index: an emerging biomarker in cardiovascular prevention.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing existing literature without systematic methodology.
PubMed 42377354 · doi:10.20960/nh.06965
What was done
This narrative review synthesized evidence evaluating the Omega-3 Index (the sum of EPA and DHA percentages in erythrocyte membranes) as a biomarker for cardiometabolic risk and all-cause mortality compared to self-reported dietary intake questionnaires.
What was found
The review reported that an Omega-3 Index below 4% is associated with a very high risk of cardiovascular events and sudden death, whereas levels above 8% indicate high cardiovascular protection. The index showed stronger correlation with cardioprotective effects than dietary intake estimates. No specific effect sizes, hazard ratios, or study counts were reported in the abstract.
Why it matters
It highlights tissue-level fatty acid incorporation as an objective biomarker that may resolve inconsistencies in omega-3 clinical trials relying solely on estimated intake.
Limits
The paper is a non-systematic narrative review providing broad threshold ranges without new empirical data, search parameters, or detailed statistical reporting. Confounding variables and patient population characteristics across cited studies were not detailed in the abstract.
Cited by
- supports Reductions in all-cause mortality, cancer, dementia, and heart disease are associated with raising the red blood cell omega-3 index from 4% to 8%.